Web Analytics
IPHA (NASDAQ) Stock Analysis | INNATE PHARMA – Deepscope
MARKET

Select Market Data Region

IPHA — INNATE PHARMA (Healthcare >> Biotechnology)

IPHA FAQ

What is IPHA's ROE?

INNATE PHARMA reports a Return on Equity (ROE) of 466.96%.

What is IPHA's dividend yield?

INNATE PHARMA offers a dividend yield of 0.00%.

What is IPHA's Deepscope Quality Score?

Deepscope rates IPHA's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy IPHA?

Deepscope's AI Timing Score for IPHA is 94 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does IPHA belong to?

INNATE PHARMA is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.

Stock Check   *Daily update data at 9:30 AM*
(Price: 2026-06-05 | FS: 2026-03-31)

IPHA

INNATE PHARMA
USD 1.71
-0.08 (-4.47%) Day Change
-0.41
D/E
467.0%
ROE
-161.6%
ROA
0.00%
Div Yield
USD 1.71
Price
-0.08 (-4.47%)
Day Change
NEWS SCORE: 84

IPHA, the overall quality is not good ( Quality = 46) but the timing to buy is ...(Sign In to See)...

46

QUALITY

Signal
UNDERPERFORM
Signal Description
Company financial health is Not Good
Reason
ROA is relatively low.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal
OUTPERFORM
Signal Descri...
Good
Reason
Lorem ipsum dolor sit amet
Sign in to see timing analysis
Unlock timing signals and detailed reasons
Sign in free

In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...

Quality Factors 48%
X
X
X
X
  In Recommendations? Not in any sections
  Select Rate 0.00 From 30 days period
  Watch Rate 0.00 From 30 days period
  News Score 84
  Magic Formula Rank by ROA
N/A
  Magic Formula Rank by ROE
N/A
  Magic Formula Rank by ROIC
N/A
  Price 1.71
  PBV / Sector
-7.75 / 4.63
  Earning Per Share -1.03
  PE / Sector
N/A / 17.43
  PEG or PE/Growth / Sector
N/A / 0.53
  Average 1M Daily Value
0.33 M
GREAT
  Average 1W Daily Value
0.04 M
GREAT
Timing Factors 42%
  MACD
  MACD Signal
  MACD Divergence
  RSI
  Stochastic Oscillator K
  Stochastic Oscillator D
  ADX
  Avg 5 day Timing Score
Financial Health 45%
X
X
X
X
  DE / Sector
  DE Average / Sector
  DE Change Average (%) / Sector
  Current Ratio / Sector
  Current Ratio Average / Sector
  Current Ratio Change Average (%) / Sector
  Quick Ratio / Sector
  Quick Ratio Average / Sector
  Quick Ratio Change Average (%) / Sector
  FCF/Share / Sector
  FCF/Share Average / Sector
  FCF/Share Change Average (%) / Sector
Ability to Make Profit 64%
X
X
X
X
X
X
X
  GPM (%) / Sector
  GPM Average (%) / Sector
  GPM Change Average (%) / Sector
  OPM (%) / Sector
  OPM Average (%) / Sector
  OPM Change Average (%) / Sector
  NPM (%) / Sector
-10,232.82 / 449.48
  NPM Average (%) / Sector
-2,500.93 / -1,506.49
  NPM Change Average (%) / Sector
833.00 / 4,940.99
GREAT
  Asset Turnover / Sector
  Asset Turnover Average / Sector
  Asset Turnover Change Average (%) / Sector
  ROA (%) / Sector
-161.59 / 30.58
  ROA Average (%) / Sector
-63.37 / -347.17
  ROA Change Average (%) / Sector
257.11 / 5,125.52
GREAT
  ROE (%) / Sector
466.96 / -3.58
GREAT
  ROE Average (%) / Sector
2.35 / 40.65
  ROE Change Average (%) / Sector
904.65 / 2,109.80
GREAT
  ROIC (%) / Sector
  ROIC Average (%) / Sector
  ROIC Change Average (%) / Sector
Return to Investors 4%
X
  Dividend (%) / Sector
N/A / 0.05
  Dividend Average (%) / Sector
N/A / 16.49
  Dividend Change Average (%) / Sector
N/A / 4.17
Registration Details
X
  Analyze Date 2026-06-06 09:08:47
  Symbol IPHA
  Name INNATE PHARMA
  Sector Healthcare >> Biotechnology
  Market NASDAQ
  Listed Shares 93.90 M
  Par Value N/A
  Calculated From Quarter
  Sign N/A
  Market Cap (M.USD) / Sector Average 168.09 / 8,857.28
News, Concensus, ...
  Estimation Consensus See at WSJ.com
  Full details See at WSJ.com
  Chart See in Chart feature
  News See at Yahoo Finance

Address: 117, Avenue de Luminy, Marseille, France, 13009

Phone: 33 4 30 30 30 30

Website: https://www.innate-pharma.com

Employees: 164

Sector: Healthcare >> Biotechnology

Description: Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.

ME vs SECTOR Healthcare >> Biotechnology

IPHA (ME)
Sector Peers
Bubble size = Market Cap

Click a bubble to view stock details  ·  Bubble size represents market capitalization share

News

Smart picks. Just WOW stocks/funds/ETFs. No noise like other tools.
IPHA
IPHA
USD 1.71 (-4.47%)
+ Watch + Port Chart